Clinical relevance of substitutions in the connection subdomain and RNase H domain of HIV-1 reverse transcriptase from a cohort of antiretroviral treatment-naïve patients.

[1]  P. Harrigan,et al.  Connection Domain Mutations N348I and A360V in HIV-1 Reverse Transcriptase Enhance Resistance to 3′-Azido-3′-deoxythymidine through Both RNase H-dependent and -independent Mechanisms , 2008, Journal of Biological Chemistry.

[2]  V. Pathak,et al.  HIV-1 reverse transcriptase connection subdomain mutations reduce template RNA degradation and enhance AZT excision , 2008, Proceedings of the National Academy of Sciences.

[3]  Elio A. Abbondanzieri,et al.  Dynamic binding orientations direct activity of HIV reverse transcriptase , 2008, Nature.

[4]  S. Sarafianos,et al.  Molecular biology: An HIV secret uncovered , 2008, Nature.

[5]  B. Roquebert,et al.  The involvement of HIV-1 RNAse H in resistance to nucleoside analogues. , 2008, The Journal of antimicrobial chemotherapy.

[6]  M. Soares,et al.  Conservation Patterns of HIV-1 RT Connection and RNase H Domains: Identification of New Mutations in NRTI-Treated Patients , 2008, PloS one.

[7]  S. Sarafianos,et al.  Amino Acid Mutation N348I in the Connection Subdomain of Human Immunodeficiency Virus Type 1 Reverse Transcriptase Confers Multiclass Resistance to Nucleoside and Nonnucleoside Reverse Transcriptase Inhibitors , 2008, Journal of Virology.

[8]  B. Wynhoven,et al.  N348I in the Connection Domain of HIV-1 Reverse Transcriptase Confers Zidovudine and Nevirapine Resistance , 2007, PLoS medicine.

[9]  J. Mellors,et al.  Mechanisms by Which the G333D Mutation in Human Immunodeficiency Virus Type 1 Reverse Transcriptase Facilitates Dual Resistance to Zidovudine and Lamivudine , 2007, Antimicrobial Agents and Chemotherapy.

[10]  M. Wainberg,et al.  Variations in Reverse Transcriptase and RNase H Domain Mutations in Human Immunodeficiency Virus Type 1 Clinical Isolates Are Associated with Divergent Phenotypic Resistance to Zidovudine , 2007, Antimicrobial Agents and Chemotherapy.

[11]  V. DeGruttola,et al.  The reverse transcriptase 67N 70R 215Y genotype is the predominant TAM pathway associated with virologic failure among HIV type 1C-infected adults treated with ZDV/ddI-containing HAART in southern Africa. , 2007, AIDS research and human retroviruses.

[12]  W. Sugiura,et al.  Drug-resistant HIV-1 prevalence in patients newly diagnosed with HIV/AIDS in Japan. , 2007, Antiviral research.

[13]  V. Pathak,et al.  Selection of Mutations in the Connection and RNase H Domains of Human Immunodeficiency Virus Type 1 Reverse Transcriptase That Increase Resistance to 3′-Azido-3′-Dideoxythymidine , 2007, Journal of Virology.

[14]  V. Pathak,et al.  Mutations in Human Immunodeficiency Virus Type 1 RNase H Primer Grip Enhance 3′-Azido-3′-Deoxythymidine Resistance , 2007, Journal of Virology.

[15]  V. Calvez,et al.  Relationship between mutations in HIV‐1 RNase H domain and nucleoside reverse transcriptase inhibitors resistance mutations in naïve and pre‐treated HIV infected patients , 2007, Journal of medical virology.

[16]  V. Pathak,et al.  Mutations in the connection domain of HIV-1 reverse transcriptase increase 3′-azido-3′-deoxythymidine resistance , 2007, Proceedings of the National Academy of Sciences.

[17]  R. Shafer,et al.  Genotypic predictors of human immunodeficiency virus type 1 drug resistance , 2006, Proceedings of the National Academy of Sciences.

[18]  J. Mellors,et al.  Reverse transcriptase mutations 118I, 208Y, and 215Y cause HIV-1 hypersusceptibility to non-nucleoside reverse transcriptase inhibitors , 2006, AIDS.

[19]  B. Clotet,et al.  Thymidine Analogue Mutation Profiles: Factors Associated with Acquiring Specific Profiles and their Impact on the Virological Response to Therapy , 2005, Antiviral therapy.

[20]  Lynn Morris,et al.  Impact of HIV-1 Subtype and Antiretroviral Therapy on Protease and Reverse Transcriptase Genotype: Results of a Global Collaboration , 2005, PLoS medicine.

[21]  F. Brun-Vézinet,et al.  French National Sentinel Survey of Antiretroviral Drug Resistance in Patients With HIV-1 Primary Infection and in Antiretroviral-Naive Chronically Infected Patients in 2001-2002 , 2005, Journal of acquired immune deficiency syndromes.

[22]  V. Pathak,et al.  Mechanism for nucleoside analog-mediated abrogation of HIV-1 replication: balance between RNase H activity and nucleotide excision. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[23]  V. Pathak,et al.  Antiretroviral Drug Resistance Mutations in Human Immunodeficiency Virus Type 1 Reverse Transcriptase Increase Template-Switching Frequency , 2004, Journal of Virology.

[24]  W. Heneine,et al.  The epidemiology of antiretroviral drug resistance among drug-naive HIV-1-infected persons in 10 US cities. , 2004, The Journal of infectious diseases.

[25]  M. Peeters,et al.  Comparison of Drug Resistance Mutations and Their Interpretation in Patients Infected With Non-B HIV-1 Variants and Matched Patients Infected With HIV-1 Subtype B , 2004, Journal of acquired immune deficiency syndromes.

[26]  M. Wulfsohn,et al.  Genotypic and phenotypic predictors of the magnitude of response to tenofovir disoproxil fumarate treatment in antiretroviral-experienced patients. , 2004, The Journal of infectious diseases.

[27]  C. Petropoulos,et al.  Natural Variation of Drug Susceptibility in Wild-Type Human Immunodeficiency Virus Type 1 , 2004, Antimicrobial Agents and Chemotherapy.

[28]  V. Calvez,et al.  Thymidine analogue reverse transcriptase inhibitors resistance mutations profiles and association to other nucleoside reverse transcriptase inhibitors resistance mutations observed in the context of virological failure , 2004, Journal of medical virology.

[29]  J. Church,et al.  ANTIRETROVIRAL-DRUG RESISTANCE AMONG PATIENTS RECENTLY INFECTED WITH HIV , 2003, Pediatrics.

[30]  B. Canard,et al.  The Molecular Mechanism of Multidrug Resistance by the Q151M Human Immunodeficiency Virus Type 1 Reverse Transcriptase and Its Suppression Using α-Boranophosphate Nucleotide Analogues* , 2002, The Journal of Biological Chemistry.

[31]  B. Rodés,et al.  Prevalence of G333D/E in naive and pretreated HIV-infected patients. , 2002, AIDS research and human retroviruses.

[32]  Michael A. Parniak,et al.  A Tight-Binding Mode of Inhibition Is Essential for Anti-Human Immunodeficiency Virus Type 1 Virucidal Activity of Nonnucleoside Reverse Transcriptase Inhibitors , 2002, Antimicrobial Agents and Chemotherapy.

[33]  B. Larder,et al.  Broad nucleoside-analogue resistance implications for human immunodeficiency virus type 1 reverse-transcriptase mutations at codons 44 and 118. , 2002, The Journal of infectious diseases.

[34]  S. Sarafianos,et al.  Selective Excision of AZTMP by Drug-Resistant Human Immunodeficiency Virus Reverse Transcriptase , 2001, Journal of Virology.

[35]  D. Pillay,et al.  Analysis of prevalence of HIV-1 drug resistance in primary infections in the United Kingdom , 2001, BMJ : British Medical Journal.

[36]  A. D. Clark,et al.  Crystal structure of HIV‐1 reverse transcriptase in complex with a polypurine tract RNA:DNA , 2001, The EMBO journal.

[37]  M. Mouroux,et al.  Prevalence and Conditions of Selection of E44D/A and V118I Human Immunodeficiency Virus Type 1 Reverse Transcriptase Mutations in Clinical Practice , 2001, Antimicrobial Agents and Chemotherapy.

[38]  S. Oka,et al.  Rapid and Simple Phenotypic Assay for Drug Susceptibility of Human Immunodeficiency Virus Type 1 Using CCR5-Expressing HeLa/CD4+ Cell Clone 1-10 (MAGIC-5) , 2001, Antimicrobial Agents and Chemotherapy.

[39]  K. Hertogs,et al.  Drug-resistant reverse transcriptase genotyping and phenotyping of B and non-B subtypes (F and A) of human immunodeficiency virus type I found in Brazilian patients failing HAART. , 2000, Virology.

[40]  G. Maga,et al.  Selective Interaction of the Human Immunodeficiency Virus Type 1 Reverse Transcriptase Nonnucleoside Inhibitor Efavirenz and Its Thio-Substituted Analog with Different Enzyme-Substrate Complexes , 2000, Antimicrobial Agents and Chemotherapy.

[41]  A. Mian,et al.  A mechanism of AZT resistance: an increase in nucleotide-dependent primer unblocking by mutant HIV-1 reverse transcriptase. , 1999, Molecular cell.

[42]  John W. Mellors,et al.  A Novel Polymorphism at Codon 333 of Human Immunodeficiency Virus Type 1 Reverse Transcriptase Can Facilitate Dual Resistance to Zidovudine and l-2′,3′-Dideoxy-3′-Thiacytidine , 1998, Journal of Virology.

[43]  H. Mitsuya,et al.  Comparative enzymatic study of HIV-1 reverse transcriptase resistant to 2',3'-dideoxynucleotide analogs using the single-nucleotide incorporation assay. , 1997, Biochemistry.

[44]  志村 和也.  Broad antiretroviral activity and resistance profile of the novel human immunodeficiency virus integrase inhibitor elvitegravir (JTK-303/GS-9137) , 2008 .